PRQR

ProQR Therapeutics N.V. PRQR

NasdaqSmall CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #2,420 of 2,925

Why it scores 32Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$4.69M

Quarter to Dec 31

Net income

$-8.92M

Quarter to Dec 31

Free cash flow

$-13.88M

Quarter to Dec 31

Operating margin

-194.0%

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$112.00M total
ADAGE CAPITAL PARTNERS GP, L.L.C.
$16.77M+44.2%
abrdn plc
$16.61M+169.3%
Affinity Asset Advisors, LLC
$10.31M+125.9%
Privium Fund Management B.V.
$10.27M+1.0%
Ikarian Capital, LLC
$6.37M+129.6%
Woodline Partners LP
$6.10MNew
HEIGHTS CAPITAL MANAGEMENT, INC
$5.14MNew
MORGAN STANLEY
$3.29M+36.0%
SPHERA FUNDS MANAGEMENT LTD.
$3.27MNew
Kynam Capital Management, LP
$2.91M0.0%
DAFNA Capital Management LLC
$2.85M-2.4%
Squadron Capital Management LLC
$2.81MNew
683 Capital Management, LLC
$2.59MNew
CITADEL ADVISORS LLC
$2.20M+68.4%
PLATINUM INVESTMENT MANAGEMENT LTD
$2.16M-6.2%
TWO SIGMA INVESTMENTS, LP
$2.12M+23.9%
Eversept Partners, LP
$1.90MNew
BOOTHBAY FUND MANAGEMENT, LLC
$1.76M+167.0%
DIADEMA PARTNERS LP
$1.72M+414.2%
UBS Group AG
$1.19M+109.4%
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$1.15M0.0%
M28 Capital Management LP
$1.12M0.0%
RAYMOND JAMES FINANCIAL INC
$1.06M+4.6%
JANE STREET GROUP, LLC
$846.5K+1267.1%
StemPoint Capital LP
$801.8KNew
See all 69 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q4 2025
EDGAR

Net Income

Q4 2025
EDGAR

Operating Margin

Q4 2025
EDGAR

ROIC

Q4 2025
EDGAR

Free Cash Flow

Q4 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/PRQR

Earnings Per Share

13fpro.ai/company/PRQR

Loading ratio trend…

PRQR key financials by period

Reported revenue, net income and operating margin by fiscal year, from ProQR Therapeutics N.V.'s annual filings on SEC EDGAR.

ProQR Therapeutics N.V. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$15.9M$-42.2M—
FY 2024$18.9M$-27.8M-161.2%
FY 2023$6.5M$-28.1M—
FY 2022$3.6M$-64.4M—
FY 2021$1.4M$-60.7M—
Source: PRQR filings on SEC EDGAR →

Companies similar to PRQR

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

PRQR insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About ProQR Therapeutics N.V. (PRQR): stock profile, AI score and financials

ProQR Therapeutics N.V. (PRQR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PRQR at 31.7/100 on a composite quality score built from its SEC filings, placing it at rank #2,420 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q4 2025), ProQR Therapeutics N.V. reports quarterly revenue of $4.7M, net income of $-8.9M, an operating margin of -194.0%. Top institutional holders of PRQR by reported 13-F value include ADAGE CAPITAL PARTNERS GP, L.L.C., abrdn plc, Affinity Asset Advisors, based on the most recent SEC filings. PRQR trades on the Nasdaq exchange and files with the SEC under CIK 1612940. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRQR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ProQR Therapeutics N.V. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1612940 →